Two years of treatment with Verzenio (abemaciclib) in combination with endocrine therapy (ET) reduces the relative risk of death by 15.8% compared to...

THURSDAY, Oct. 23, 2025 -- For patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive, high-risk...

Adding abemaciclib to standard endocrine therapy reduces the risk of death and recurrence in patients with breast cancer.

A new study published in JAMA Network Open has found that Ghanaian women and U.S. non-Hispanic Black women have nearly identical rates of estrogen...

A new study published in JAMA Network Open has found that Ghanaian women and U.S. non-Hispanic Black women have nearly identical rates of estrogen...

WASHINGTON — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients — revving up their immune systems to...

A recent cohort study of more than 2 million adolescent girls and women has provided the most comprehensive evaluation to date of hormonal...

Can Sucking a Woman’s Breast Really Reduce Breast Cancer Risk? Health Expert Sets the Record Straight

In a recent clinical trial, a low dose of aspirin reduced the risk of colon and rectal cancer recurrence by...

Patients with oestrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated...